SAN FRANCISCO, Aug. 9, 2026 /PRNewswire/ — Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company’s financial condition, revenue recognition, inventory distribution, and business practices.
SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW
Key ADMA Class Action Details
- Class Period: Aug. 9, 2024 – Mar. 25, 2026
- Lead Plaintiff Deadline: Aug. 10, 2026
- Visit: www.hbsslaw.com/investor-fraud/adma
- Contact the Firm Now: ADMA@hbsslaw.com 844-916-0895
Alleged Wrongdoing in ADMA Biologics Lawsuit:
The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose that:
- ADMA Biologics engaged in an undisclosed related party transaction;
- ADMA Biologics used channel stuffing to create an appearance of revenue;
- ADMA Biologics lacked adequate internal controls; and
- As a result, Defendants’ statements about ADMA Biologics’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
The Truth Emerges and Market Reaction:
The suit alleges that the misstatements were revealed through several corrective disclosure events, which wiped out substantial shareholder value, exposing investors to severe financial harm.
|
Date |
Corrective Event |
Stock Price Impact |
|
March 24, 2026 |
Culper Research publishes short-seller report revealing channel stuffing, rebates, and undisclosed related-party distributor Genesis BioPharma, triggering intense market sell-offs over two trading days as investors digest the revelations. |
-31.6% combined (March 24: Down 16.6% to $11.33) (March 25: Down 15.0% to $9.63) |
|
March 26, 2026 |
ADMA issues a press release responding to the short-seller report stating it was “taking appropriate steps to review the assertions,” alongside a stock rating downgrade from Cantor Fitzgerald, further eroding investor confidence. |
-13.9% (Down $1.34 to close at $8.29) |
View our latest video summary of the allegations: youtu.be/HzxFwXaK0fw
Hagens Berman’s Investigation
“We’re investigation whether ADMA made false and misleading statements to investors concealing the reality of its distribution channels and financial reporting, as the suit alleges” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the lawsuit’s claims.
What Affected ADMA Investors Can Do
If you invested in ADMA and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your information to Hagens Berman »
If you’d like more information and answers to frequently asked questions about the ADMA case and the firm’s investigation, read more »
Whistleblowers: Persons with non-public information regarding ADMA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ADMA@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
View original content to download multimedia:https://www.prnewswire.com/news-releases/deadline-next-week-hagens-berman-advises-adma-biologics-inc-investors-to-contact-the-firm-before-august-10-2026-302846675.html
SOURCE Hagens Berman Sobol Shapiro LLP
